Company news
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news
Supernus Pharmaceuticals, Inc. news releases on 6ix. Latest, Aug 31, 2026: Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD…
Press releases & updates
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
August 31, 2026
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
August 7, 2026
Supernus Announces Second Quarter 2026 Financial Results
August 3, 2026
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
August 3, 2026
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
July 22, 2026
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
July 14, 2026
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record
June 17, 2026
Supernus Pharmaceuticals to Participate in June Investor Conferences
May 27, 2026
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
May 6, 2026
Supernus Announces First Quarter 2026 Financial Results
May 5, 2026
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
April 22, 2026
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026
Supernus Pharmaceuticals to Participate in March Investor Conferences
February 22, 2026
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
February 12, 2026
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
December 2, 2025
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
November 11, 2025
Supernus Announces Third Quarter 2025 Financial Results
November 3, 2025
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 20, 2025
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
September 17, 2025
Supernus Pharmaceuticals to Participate in September Investor Conferences
August 26, 2025
Supernus Announces Second Quarter 2025 Financial Results
August 4, 2025
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
July 30, 2025
Sage Therapeutics Announces Second Quarter 2025 Financial Results
July 30, 2025
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
July 27, 2025
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
July 21, 2025
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
June 15, 2025
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
May 28, 2025
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
May 27, 2025
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
May 27, 2025
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
May 19, 2025
Supernus Announces First Quarter 2025 Financial Results
May 5, 2025
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
April 22, 2025
Supernus to Participate in Two Upcoming Investor Conferences
March 3, 2025
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
February 26, 2025
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
February 24, 2025
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
February 17, 2025
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
February 3, 2025
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
January 26, 2025
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 25, 2024
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
November 12, 2024
Supernus Announces Third Quarter 2024 Financial Results
November 3, 2024
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
October 30, 2024
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
October 20, 2024
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
October 16, 2024
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
October 9, 2024
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
September 23, 2024
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 18, 2024
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 27, 2024